A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.

ABSTRACT:

Background

Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a dose-ranging study, nebulized once-daily revefenacin had a long duration of action in patients after 7 days' administration of doses up to 700 μg. In this multiple-dose study, the bronchodilation efficacy and adverse events profile were characterized in patients administered nebulized revefenacin once daily for 28 days.

Methods

A total of 355 COPD patients (mean age 62 years, mean forced expiratory volume in 1 s [FEV₁] 44% of predicted) were randomized in a double-blind, placebo-controlled parallel group study. Inhaled corticosteroids as well as short-acting bronchodilators wer

SUBMITTER: Pudi KK 

PROVIDER: S-EPMC5667509 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature